Latest Pharmaceuticals News

Page 1 of 49
Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
Logan Eniac
14 Feb 2026
Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.
Victor Sage
Victor Sage
11 Feb 2026
CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.
Ada Torres
Ada Torres
11 Feb 2026
Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.
Ada Torres
Ada Torres
10 Feb 2026
EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.
Ada Torres
Ada Torres
10 Feb 2026
Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.
Victor Sage
Victor Sage
9 Feb 2026
Argo Investments has reported a half-year profit of $130.8 million and declared a record fully franked interim dividend of 18.5 cents per share, reflecting strong dividend growth despite a challenging market environment.
Claire Turing
Claire Turing
9 Feb 2026
Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.
Victor Sage
Victor Sage
9 Feb 2026
A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.
Logan Eniac
Logan Eniac
7 Feb 2026
A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.
Logan Eniac
Logan Eniac
7 Feb 2026
Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.
Ada Torres
Ada Torres
6 Feb 2026
Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.
Ada Torres
Ada Torres
5 Feb 2026